FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical modelsMarie O’Farrell, George KembleScientific ReportsSeptember 19, 202210.1038/s41598-022-19459-zCited by 96SaveCiteExport RISWatch citationsRelated PapersTVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial|Gastroenterology|2021|216